MedTrace Logo

Improving Access to HbA1c in Sub Saharan Africa

NCT01460095 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1349

Last updated 2016-04-19

No results posted yet for this study

Summary

Glycated haemoglobin (HbA1c) is the best surrogate of average blood glucose control in diabetic patients. Large-scale studies in the USA and UK have demonstrated that lowering HbA1c significantly reduces diabetes complications. Moreover, immediate feedback of HbA1c measurement to patients improves control. However, HbA1c is unavailable in most parts of Africa, a continent with one of the highest burden of diabetes. To translate these evidences, the investigators will provide affordable access to HbA1c measurement and relevant education in 2 African countries aiming significant improvement of diabetes control. The investigators will develop with local health authorities, training and cost-recovery scheme for long-term sustainability.

Conditions

Interventions

OTHER

HbA1c measurement and education

three-monthly point of care measurement of HbA1c with immediate feedback to patients and provision of interpretation and targeted one-to-one education

Sponsors & Collaborators

  • Newcastle University

    collaborator OTHER

  • University of Yaounde 1

    collaborator OTHER

  • Yaounde Central Hospital

    lead OTHER_GOV

Principal Investigators

  • Eugene Sobngwi, MD, PhD · Newcastle University, UK and Yaounde Central Hospital, Cameroon

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2011-11-30
Completion
2011-12-31

Countries

  • Cameroon
  • Guinea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01460095 on ClinicalTrials.gov